Cardiome Pharma Corp. (NASDAQ: CRME; TSX: COM) disclosed that Douglas G. Janzen, its CEO, has left the company effective immediately. Dr. William Hunter, a director of Cardiome Pharma, has been appointed interim CEO. Janzen...
Cardiome Pharma replaces CEO Doug Janzen
- Cardiome repays $20 million debt and terminates Merch line of credit
- Cardiome Pharma replaces CEO Doug Janzen
- Merck Discontinues Cardiome Pharma’s Vernakalant Oral Development